SUPPRELIN LA

<table>
<thead>
<tr>
<th>Brand Name</th>
<th>Generic Name</th>
<th>Length of Authorization</th>
</tr>
</thead>
<tbody>
<tr>
<td>Supprelin LA</td>
<td>histrelin acetate</td>
<td>Per Medical Guidelines</td>
</tr>
</tbody>
</table>

**Approvable Criteria:**

1. Is the member diagnosed with central precocious puberty (CPP)?
   - If yes, continue to #2.
   - If no, do not approve.

2. Has the diagnosis been confirmed by a measurement of blood concentrations of total sex steroids, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) following stimulation with a gonadotropin-releasing hormone (GnRH) analog and does the bone age versus chronological age assessment support the diagnosis of CPP?
   - If yes, continue to #3.
   - If no, do not approve.

3. Has the member tried and failed Lupron Depot (leuprolide acetate) and/or Synarel (nafarelin acetate)?
   - If yes, approve one implant per Calendar Year.
   - If no, do not approve.

**SPECIALTY PHARMACY PRODUCT**

**FDA-Approved Indications:** For the treatment of children with central precocious puberty. Children with central precocious puberty (neurogenic or idiopathic) have an early onset of secondary sexual characteristics (earlier than 8 years of age in females and 9 years of age in males). They also show a significantly advanced bone age, which can result in diminished adult height attainment.

Prior to initiation of treatment, a clinical diagnosis of central precocious puberty should be confirmed by measurement of blood concentrations of total sex steroids, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) following stimulation with a gonadotropin-releasing hormone (GnRH) analog, and assessment of bone age versus chronological age. Baseline evaluations should include height and weight measurements, diagnostic imaging of the brain (to rule out intracranial tumor), pelvic/testicular/adrenal ultrasound (to rule out steroid secreting tumors), human chorionic gonadotropin levels (to rule out chorionic gonadotropin secreting tumor), and adrenal steroids to exclude congenital adrenal hyperplasia.

**FDA-Approved Dosing:** One implant inserted subcutaneously every 12 months.

Discontinuation of therapy should be considered at the discretion of the health care practitioner and at the appropriate time point for the onset of puberty (approximately 11 years of age for females and 12 years of age for males).

**References:**
- Supprelin LA prescribing information May, 2007.